Accelerating Biologics Discovery and Cell Line Development with Next-Gen Cyto-Mine®
Discover how picodroplets are transforming workflows for biologics discovery and development in our latest poster.
Our latest poster, presented at BPS 2024, showcases groundbreaking advancements in biologics discovery and cell line development using Sphere Fluidics’ next-generation Cyto-Mine®. By integrating picodroplet technology, Cyto-Mine® allows for single-cell analysis, selection, and isolation—radically speeding up the discovery process while ensuring monoclonality. Whether you’re screening B cell repertoires or advancing cell line development, our second-generation Cyto-Mine® delivers unmatched precision and efficiency.
Download the full poster to explore:
Increased efficiency in gene integration and clone selection
How Cyto-Mine® enables antibody discovery through high-throughput B cell screening
Applications of Cyto-Mine® in antibody discovery and cell line development
This cutting-edge technology is helping scientists reduce timelines by 2-3 months, improve cell viability, and increase the chances of finding rare, high-producing clones.
Download the poster here:
Poster Authors: Maryam Ahmadi, Elena Shvets, Frank Gesellchen, Xin Liu, Simona Preiksaite, and Richard Hammond
Contact: Maryam.Ahmadi@spherefluidics.com | info@spherefluidics.com
References:
- Kaplon et. al., Antibodies to watch in 2022, Mabs, 2022.
- Bauer et. al., How can we discover developable antibody-based biotherapeutics?, Front Mol Biosci, 2023.
- Farid et. al., Benchmarking biopharmaceutical process development and manufacturing cost contributions to R&D, MAbs, 2020.
Discover the next generation of
Cyto-mine®
Get ready for the latest innovation in single cell analysis and isolation
The next generation of Cyto-Mine® is coming. Think Cyto-Mine®, but supercharged, enabling multiplexing and greater assay flexibility to fit your needs. It means that you can examine vastly greater numbers of cells — and isolate the most valuable ones— with unparalleled precision.
